{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:20:04Z","timestamp":1787761204027,"version":"build-2784847793"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010648","name":"KU Leuven University Hospitals Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Vessels, Thrombosis & Hemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bvth.2026.100168","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T17:30:24Z","timestamp":1776187824000},"page":"100168","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6781-1148","authenticated-orcid":false,"given":"Tom","family":"Langenaeken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Vanglabeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Van Hecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-0506","authenticated-orcid":false,"given":"Pieter","family":"De Meester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1461-3986","authenticated-orcid":false,"given":"Tom","family":"Verbelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-1706","authenticated-orcid":false,"given":"Peter","family":"Verbrugghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8428-2302","authenticated-orcid":false,"given":"Filip","family":"Rega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina U.","family":"Lorentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik I.","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-293X","authenticated-orcid":false,"given":"Bart","family":"Meuris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bvth.2026.100168_bib1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ahj.2010.05.005","article-title":"Lowering the intensity of oral anticoagulant therapy in patients with bileaflet mechanical aortic valve replacement: results from the LOWERING-IT trial","volume":"160","author":"Torella","year":"2010","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.bvth.2026.100168_bib2","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jtcvs.2014.01.004","article-title":"Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial","volume":"147","author":"Puskas","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"13","key":"10.1016\/j.bvth.2026.100168_bib3","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bvth.2026.100168_bib4","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an On-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"issue":"6","key":"10.1016\/j.bvth.2026.100168_bib5","first-page":"572","article-title":"The Medtronic Parallel valve and the lessons learned","volume":"5","author":"Bodnar","year":"1996","journal-title":"J Heart Valve Dis"},{"issue":"1","key":"10.1016\/j.bvth.2026.100168_bib6","first-page":"96","article-title":"Mechanical valve thrombosis in a chronic animal model: differences between monoleaflet and bileaflet valves","volume":"14","author":"Meuris","year":"2005","journal-title":"J Heart Valve Dis"},{"issue":"1","key":"10.1016\/j.bvth.2026.100168_bib7","first-page":"6","article-title":"Development of an orthotopic pulmonary valve replacement porcine model for mechanical heart valve thrombosis","volume":"2","author":"Langenaeken","year":"2024","journal-title":"J Card Surg"},{"issue":"4","key":"10.1016\/j.bvth.2026.100168_bib9","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"The contact activation inhibitor and factor XI antibody AB023 produces safe, dose-dependent anticoagulation: a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"10.1016\/j.bvth.2026.100168_bib10","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"Plos Biol"},{"key":"10.1016\/j.bvth.2026.100168_bib12","series-title":"Guide For The Care and Use Of Laboratory Animals","year":"2011"},{"issue":"8","key":"10.1016\/j.bvth.2026.100168_bib13","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/blood-2007-10-120139","article-title":"Reduced incidence of ischemic stroke in patients with severe factor XI deficiency","volume":"111","author":"Salomon","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bvth.2026.100168_bib14","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1182\/blood-2016-09-742262","article-title":"Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events","volume":"129","author":"Preis","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bvth.2026.100168_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1160\/TH10-05-0307","article-title":"Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis","volume":"105","author":"Salomon","year":"2011","journal-title":"Thromb Haemost"},{"issue":"13","key":"10.1016\/j.bvth.2026.100168_bib16","first-page":"2587","article-title":"Factor XIIa inhibition protects against thrombus formation on artificial surfaces without increasing bleeding","volume":"115","author":"Hagedorn","year":"2010","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.bvth.2026.100168_bib17","first-page":"2212","article-title":"Factor XII and XI inhibition in models of artificial-surface thrombosis","volume":"43","author":"Schneider","year":"2022","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.bvth.2026.100168_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1084\/jem.20050664","article-title":"Defective thrombus formation in mice lacking coagulation factor XII","volume":"202","author":"Renn\u00e9","year":"2005","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.bvth.2026.100168_bib19","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1161\/ATVBAHA.107.155952","article-title":"Intrinsic pathway of coagulation and arterial thrombosis","volume":"27","author":"Gailani","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"19","key":"10.1016\/j.bvth.2026.100168_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914433","article-title":"Inhibition of factor XI: a new era in the treatment of thromboembolic diseases","volume":"24","author":"Poenou","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.bvth.2026.100168_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.bvth.2026.100168_bib22","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bvth.2026.100168_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S0140-6736(22)00456-1","article-title":"Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study","volume":"399","author":"Piccini","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bvth.2026.100168_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"issue":"10519","key":"10.1016\/j.bvth.2026.100168_bib25","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1016\/S0140-6736(25)02097-5","article-title":"Efficacy and safety of REGN9933A2 and REGN7508Cat for preventing postoperative venous thromboembolism (ROXI-VTE-I and ROXI-VTE-II): two randomised, open-label, phase 2 trials","volume":"406","author":"Weitz","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bvth.2026.100168_bib27","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1161\/ATVBAHA.118.312328","article-title":"Contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial","volume":"39","author":"Lorentz","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Blood Vessels, Thrombosis & Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950327226000331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:26:45Z","timestamp":1787758005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950327226000331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950327226000331"],"URL":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100168","relation":{},"ISSN":["2950-3272"],"issn-type":[{"value":"2950-3272","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factor XI inhibition with gruticibart prevents mechanical valve thrombosis in a porcine pulmonary model","name":"articletitle","label":"Article Title"},{"value":"Blood Vessels, Thrombosis & Hemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bvth.2026.100168","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100168"}}